Search clinical trials for: 177Lu-R11228

Total 298 results

Radionetics Oncology

Terminated

A Phase 1 Study of 68Ga-R11228 and 177Lu-R11228 in Breast Cancer

Locoregionally Recurrent Hormone-receptor Positive Breast Cancer | Metastatic Hormone Receptor Positive Breast Cancer

United States, Australia
Ipsen

Terminated

Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1.

Gastric Cancer | Colorectal Cancer | Bone Cancer | Squamous Cell Carcinoma of the Head and Neck | Advanced Cancer | Recurrent Disease | Pancreatic Ductal Adenocarcinoma | Metastatic Tumours

United States, France, Belgium, Switzerland, Netherlands
Sidney Kimmel Comprehensive Cancer Center at Johns...
Adenoid Cystic Carcinoma Research Foundation; Progenics Pharmaceuticals, Inc.

Terminated

177Lu-PSMA (177Lu-PNT2002) in PSMA-Positive Adenoid Cystic Carcinoma

Adenoid Cystic Carcinoma

United States
Telix Pharmaceuticals (Innovations) Pty Limited
Medpace, Inc.

Recruiting

Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC (LUTEON)

Renal Cell Carcinoma (RCC) | Renal Cell Cancer Metastatic | ccRCC | Renal Cell Cancer, Recurrent | Clear Cell Renal Cell Cancer (ccRCC) | Renal Cell Carcinoma (Kidney Cancer)

Australia
The First Affiliated Hospital of Xiamen University

Completed

Evaluation of 177Lu-TATE-EB-01（LNC1010）in SSTR2-positive Tumors

SSTR2-positive Tumors

China

This is a preview

Log in or create a free account to see all matching trials and use the full search.

Log in Register

Subscribe